Cargando…

1561. Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant

BACKGROUND: Resistant or refractory CMV infections are not well defined and may be associated with high morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. Suspicion of resistant CMV infections is usually based on suboptimal responses to antiviral agents. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artau, Annette, Aitken, Samuel L, Batista, Marjorie, Chaer, Firas El, Prayag, Amrita, Haddad, Lynn El, Mulanovich, Victor, Ariza-Heredia, Ella, Chemaly, Roy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252448/ http://dx.doi.org/10.1093/ofid/ofy210.1389

Ejemplares similares

1538. High Mortality of Cytomegalovirus (CMV) Pneumonia in Hematopietic Cell Transplant Recipients
por: Batista, Marjorie, et al.
Publicado: (2018)

Active Mycobacterium tuberculosis infection at a comprehensive cancer center, 2006–2014
por: Kmeid, Joumana, et al.
Publicado: (2019)

Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients
por: Foolad, Farnaz, et al.
Publicado: (2017)

568. Healthcare Cost and Length of Stay for Cytomegalovirus (CMV) Infection-Related Hospitalizations in Allogeneic Hematopoietic Cell Transplant (allo-HCT) recipients: A Multicenter Analysis
por: Khawaja, Fareed, et al.
Publicado: (2020)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

789. Comparison of Interferon-γ Release Assays (IGRAs) for Diagnosis of Latent or Active Tuberculosis in Cancer Patients
por: Kulkarni, Prathit, et al.
Publicado: (2018)

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant
por: Ariza-Heredia, Ella J, et al.
Publicado: (2023)

940. The use of a commercially available CMV T Cell Immunity Panel to Assess the Risk of CMV Infections in Hematopoietic Cell Transplant Recipients with Low Level CMV Viremia
por: Khawaja, Fareed, et al.
Publicado: (2021)

Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes
por: El Chaer, Firas, et al.
Publicado: (2017)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
por: El Chaer, Firas, et al.
Publicado: (2022)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

1583. The Utility of the Immunodeficiency Scoring Index (ISI) to Predict Outcomes of Coronavirus (HCoV) Infections in Hematopietic Cell Transplant (HCT) Recipients
por: Khawaja, Fareed, et al.
Publicado: (2018)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
por: Marty, Francisco M, et al.
Publicado: (2018)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

2119. Predictive Value of the Immunodeficiency Scoring Index for COVID-19 Related Outcomes in Hematopoietic Transplant Recipients
por: Daher, Marilyne, et al.
Publicado: (2022)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2023)

Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Lee, Sae-Mi, et al.
Publicado: (2017)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

P1561: HBSAG-POSITIVE PATIENTS WITH CO-REACTIVATION OF CYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUSES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ASSOCIATED WITH POOR SURVIVAL
por: Ren, Jinhua, et al.
Publicado: (2023)

Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention
por: Wilson Dib, Rita, et al.
Publicado: (2023)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2021)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2023)

1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children’s Hospital
por: Galetaki, Despoina M, et al.
Publicado: (2019)

The Successful Recovery of Bacteriophages with Activity against Vancomycin-Resistant Enterococci (VRE) from Stool Samples of Hematopoietic Cell Transplant (HCT) Recipients
por: El Haddad, Lynn, et al.
Publicado: (2017)

Cytomegalovirus (CMV) Disease Despite Weekly Preemptive CMV Strategy for Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, I P, et al.
Publicado: (2018)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
por: Khawaja, Fareed, et al.
Publicado: (2022)

Clinical and Economic Burden of Respiratory Viral Infections in Hematopoietic Stem Cell Transplant Recipients: The MD Anderson Experience
por: Ghantoji, Shashank S, et al.
Publicado: (2017)

CMV viral load in bronchoalveolar lavage for diagnosis of pneumonia in allogeneic hematopoietic stem cell transplantation
por: Iglesias, L, et al.
Publicado: (2017)

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV‐specific T cells
por: McGuire, Helen M, et al.
Publicado: (2020)

Impact of CMV PCR Blips in Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Lodding, Isabelle P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nb1p3durbigd2hsbul7gr4ckjq